GLASSIA
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- GLASSIA
- Generic name
- ALPHA.1-PROTEINASE INHIBITOR HUMAN
- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 83473cbb-48e4-42a2-81b6-4c851423da7b
- SPL ID
- 312a9f40-d4bd-4cc2-810a-2df7d7baead8
- Version
- 31
- Effective date
- 2025-12-02
- Source export date
- 2026-11-13
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/df974ce21ba33b4471866e2af5412327fbd4bcd68d14b42d7cfb3aa15d163738/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:54:49
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 125325 | derived:openfda.application_number |
| application number | BLA125325 | openfda.application_number | |
| brand name | GLASSIA | openfda.brand_name | |
| generic name | ALPHA.1-PROTEINASE INHIBITOR HUMAN | openfda.generic_name | |
| manufacturer name | Takeda Pharmaceuticals America, Inc. | openfda.manufacturer_name | |
| ndc | package | 0944-2884-06 | openfda.package_ndc |
| ndc | package | 0944-2884-03 | openfda.package_ndc |
| ndc | package | 0944-2884-01 | openfda.package_ndc |
| ndc | package | 0944-2884-05 | openfda.package_ndc |
| ndc | package | 0944-2884-04 | openfda.package_ndc |
| ndc | package | 0944-2884-02 | openfda.package_ndc |
| ndc | product | 0944-2884 | openfda.product_ndc |
| ndc11 | package | 00944288402 | derived:openfda.package_ndc |
| ndc11 | package | 00944288406 | derived:openfda.package_ndc |
| ndc11 | package | 00944288404 | derived:openfda.package_ndc |
| ndc11 | package | 00944288405 | derived:openfda.package_ndc |
| ndc11 | package | 00944288401 | derived:openfda.package_ndc |
| ndc11 | package | 00944288403 | derived:openfda.package_ndc |
| rxcui | 1661208 | openfda.rxcui | |
| rxcui | 1013867 | openfda.rxcui | |
| spl id | 312a9f40-d4bd-4cc2-810a-2df7d7baead8 | id | |
| spl set id | 83473cbb-48e4-42a2-81b6-4c851423da7b | set_id | |
| unii | F43I396OIS | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Severe hypersensitivity and anaphylactic reactions may occur in IgA deficient patients with antibodies against IgA and in patients with a history of hypersensitivity to other Alpha 1- PI products. ( 5.1 ) May carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.2 ) 5.1 Hypersensitivity Reactions GLASSIA may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing severe hypersensitivity and anaphylactic reactions. Monitor vital signs continuously and observe the patient carefully throughout the infusion. Discontinue the infusion if hypersensitivity symptoms occur and administer appropriate emergency treatment. Have epinephrine and/or other appropriate supportive therapy available for the treatment of any acute anaphylactic or anaphylactoid reaction. 5.2 Transmissible Infectious Agents Because this product is made from human plasma, it may carry a risk of transmitting infectious agents, such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. The risk of transmitting an infectious agent has been minimized by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections and by inactivating and removing certain viruses during the manufacturing process. Despite these measures, such products may still potentially transmit human pathogenic agents. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. No seroconversions for hepatitis B or C (HBV or HCV) or human immunodeficiency virus (HIV) or any other known infectious agent were reported with the use of GLASSIA during the clinical trials.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The serious adverse reaction observed during clinical trials with GLASSIA was exacerbation of chronic obstructive pulmonary disease (COPD). The most common adverse reactions during clinical trials were headache and upper respiratory infection. The most common adverse reactions in clinical trials were headache and upper respiratory infection. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety profile of GLASSIA was evaluated in a randomized, double-blind, active-control trial and an open-label, non-parallel, dose-escalation trial, in 65 subjects with pre-augmentation therapy serum Alpha 1 -PI levels less than 11 microM. In the randomized, double-blind, active-control trial, 50 subjects received weekly infusions of GLASSIA or the comparator Alpha 1 -PI product, Prolastin, at a dosage of 60 mg/kg for a total of 12 doses after which all subjects remaining in the trial were treated for another 12 weeks with GLASSIA only. Overall, 17 subjects received 12 doses and 32 subjects received 22 - 24 doses of GLASSIA during the trial. (One subject randomized to the comparator Alpha 1 -PI product did not receive any treatment with GLASSIA during the last 12 weeks of the trial.). In the open label, non-parallel, dose-escalation trial, 18 subjects received a single infusion of GLASSIA at dosages of 30, 60 or 120 mg/kg. The population treated in the two trials was 40-74 years old, 54% male, 100% Caucasian. Tables 1 and 2 compare the adverse reactions reported during the initial 12 weeks (double-blind portion) of the randomized, active comparator trial in all subjects treated with GLASSIA with reactions in the concurrent Prolastin control group. Table 3 compares the frequency of adverse reactions as a percentage of all infusions for GLASSIA and Prolastin-treated subjects over the entire trial period. Table 1: Number of Subjects/Infusions/Adverse Reactions An adverse reaction is any adverse event which met any of the following criteria: (a) an adverse event that began within 72 hours following the end of product infusion, or (b) an adverse event considered by either the investigator or sponsor to be at least possibly related to product administration, or (c) an adverse event for which causality assessment was missing or indeterminate. Occurring during the First 12 Weeks of Treatment Assessed Parameters GLASSIA Prolastin No. of subjects treated 33 17 No. of infusions 393 190 No. of subjects with serious adverse reactions (%) 1 (3%) 1 (6%) No. of subjects experiencing an adverse reaction (%) 22 (67%) 15 (88%) No. of adverse reactions 47 39 Table 2: Adverse Reactions An adverse reaction is any adverse event which met any of the following criteria: (a) an adverse event that began within 72 hours following the end of product infusion, or (b) an adverse event considered by either the investigator or sponsor to be at least possibly related to product administration, or (c) an adverse event for which causality assessment was missing or indeterminate. Occurring in > 5% of Subjects during the First 12 Weeks of Treatment Adverse Reactions (AR) GLASSIA (N=33) No. of subjects with adverse reactions (AR) (percentage of all subjects) Prolastin (N=17) No. of subjects with adverse reactions (AR) (percentage of all subjects) Cough 3 (9%) 4 (24%) Headache 3 (9%) 3 (18%) Sinusitis 3 (9%) 1 (6%) Upper respiratory tract infection 3 (9%) 0 (0%) Chest discomfort 2 (6%) 0 (0%) Dizziness 2 (6%) 0 (0%) Hepatic enzyme increased 2 (6%) 0 (0%) Table 3: Adverse Reactions An adverse reaction is any adverse event which met any of the following criteria: (a) an adverse event that began within 72 hours following the end of product infusion, or (b) an adverse event considered by either the investigator or sponsor to be at least possibly related to product administration, or (c) an adverse event for which causality assessment was missing or indeterminate. Frequency as a % of all Infusions (≥ 0.5%) Adverse Reactions (AR) GLASSIA Throughout entire 24-week double-blind plus open-label trial period. (N i =960) No. of adverse reactions (AR) (percentage of all infusions) Prolastin Throughout initial 12-week double-blind period. (N i =190) No. of adverse reactions (AR) (percentage of all infusions) N i =number of infusions. Upper respiratory tract infection 8 (0.8%) 0 (0.0%) Headache 6 (0.6%) 3 (1.6%) Nasopharyngitis 5 (0.5%) 0 (0%) Chronic Obstructive Pulmonary Disease (COPD) Exacerbations During the 12-week double blind portion of the randomized, active comparator trial, 4 subjects (12%) had a total of 7 exacerbations of chronic obstructive pulmonary disease (COPD) during GLASSIA treatment and 5 subjects (29%) had a total of 6 exacerbations of COPD during Prolastin treatment. Seventeen additional exacerbations in 14 subjects (28%) occurred during the 12-week open-label treatment period with GLASSIA. The overall rate of pulmonary exacerbations during treatment with either product was 1.3 exacerbations per subject per year. Testing for viral markers for HBV, HCV, HIV-1 and HIV-2 showed no seroconversions during either trial. Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to GLASSIA with the incidence of antibodies to other products may be misleading. In the double blind, randomized, active comparator trial of GLASSIA, low level anti-GLASSIA antibodies were detected in one subject at one time point (Week 12) and returned to negative at the end of the study (Week 24) despite continuous exposure to GLASSIA. No immune system adverse reactions were reported. Immunogenicity was further evaluated in the multicenter study (post-licensure) in subjects with Alpha 1 -PI deficiency. Of the 34 subjects studied, 2 (6%) developed neutralizing anti-Alpha 1 -PI antibodies. There was no association between patients with Alpha 1 -PI antibodies and immune-mediated treatment emergent adverse reactions or associated decrease in plasma Alpha 1 -PI levels. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of GLASSIA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Respiratory, Thoracic, and Mediastinal Disorders : Dyspnea Gastrointestinal Disorders : Nausea General Disorders and Administration Site Conditions : Fatigue
adverse reactions table
<table ID="t1" width="100%"><caption>Table 1: Number of Subjects/Infusions/Adverse Reactions<footnote ID="tb1ft1">An adverse reaction is any adverse event which met any of the following criteria: (a) an adverse event that began within 72 hours following the end of product infusion, or (b) an adverse event considered by either the investigator or sponsor to be at least possibly related to product administration, or (c) an adverse event for which causality assessment was missing or indeterminate.</footnote> Occurring during the First 12 Weeks of Treatment</caption><col width="64%" align="left"/><col width="18%" align="left"/><col width="18%" align="left"/><thead><tr><th align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">Assessed Parameters</th><th align="center" valign="top" styleCode="Toprule Botrule Rrule">GLASSIA</th><th align="center" valign="top" styleCode="Toprule Botrule Rrule">Prolastin</th></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule">No. of subjects treated</td><td align="center" valign="top" styleCode="Botrule Rrule">33</td><td align="center" valign="top" styleCode="Botrule Rrule">17</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule">No. of infusions</td><td align="center" valign="top" styleCode="Botrule Rrule">393</td><td align="center" valign="top" styleCode="Botrule Rrule">190</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule">No. of subjects with serious adverse reactions<footnoteRef IDREF="tb1ft1"/> (%) </td><td align="center" valign="top" styleCode="Botrule Rrule">1 (3%)</td><td align="center" valign="top" styleCode="Botrule Rrule">1 (6%)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule">No. of subjects experiencing an adverse reaction<footnoteRef IDREF="tb1ft1"/> (%)</td><td align="center" valign="top" styleCode="Botrule Rrule">22 (67%)</td><td align="center" valign="top" styleCode="Botrule Rrule">15 (88%)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule">No. of adverse reactions<footnoteRef IDREF="tb1ft1"/></td><td align="center" valign="top" styleCode="Botrule Rrule">47</td><td align="center" valign="top" styleCode="Botrule Rrule">39</td></tr></tbody></table>
adverse reactions table
<table ID="t2" width="100%"><caption>Table 2: Adverse Reactions<footnote ID="tb2ft1">An adverse reaction is any adverse event which met any of the following criteria: (a) an adverse event that began within 72 hours following the end of product infusion, or (b) an adverse event considered by either the investigator or sponsor to be at least possibly related to product administration, or (c) an adverse event for which causality assessment was missing or indeterminate.</footnote> Occurring in > 5% of Subjects during the First 12 Weeks of Treatment</caption><col width="37%" align="left"/><col width="32%" align="left"/><col width="31%" align="left"/><thead><tr><th align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">Adverse Reactions (AR)</th><th align="center" valign="middle" styleCode="Toprule Botrule Rrule">GLASSIA (N=33) No. of subjects with adverse reactions<footnoteRef IDREF="tb2ft1"/> (AR) (percentage of all subjects) </th><th align="center" valign="middle" styleCode="Toprule Botrule Rrule">Prolastin (N=17) No. of subjects with adverse reactions<footnoteRef IDREF="tb2ft1"/> (AR) (percentage of all subjects)</th></tr></thead><tbody><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule">Cough</td><td align="center" valign="middle" styleCode="Botrule Rrule">3 (9%)</td><td align="center" valign="middle" styleCode="Botrule Rrule">4 (24%)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule">Headache</td><td align="center" valign="middle" styleCode="Botrule Rrule">3 (9%)</td><td align="center" valign="middle" styleCode="Botrule Rrule">3 (18%)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule">Sinusitis</td><td align="center" valign="middle" styleCode="Botrule Rrule">3 (9%)</td><td align="center" valign="middle" styleCode="Botrule Rrule">1 (6%)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule">Upper respiratory tract infection</td><td align="center" valign="middle" styleCode="Botrule Rrule">3 (9%)</td><td align="center" valign="middle" styleCode="Botrule Rrule">0 (0%)</td></tr><tr><td align="justify" valign="top" styleCode="Botrule Lrule Rrule">Chest discomfort</td><td align="center" valign="middle" styleCode="Botrule Rrule">2 (6%)</td><td align="center" valign="middle" styleCode="Botrule Rrule">0 (0%)</td></tr><tr><td align="justify" valign="top" styleCode="Botrule Lrule Rrule">Dizziness</td><td align="center" valign="middle" styleCode="Botrule Rrule">2 (6%)</td><td align="center" valign="middle" styleCode="Botrule Rrule">0 (0%)</td></tr><tr><td align="justify" valign="top" styleCode="Botrule Lrule Rrule">Hepatic enzyme increased</td><td align="center" valign="middle" styleCode="Botrule Rrule">2 (6%)</td><td align="center" valign="middle" styleCode="Botrule Rrule">0 (0%)</td></tr></tbody></table>
adverse reactions table
<table ID="t3" width="100%"><caption>Table 3: Adverse Reactions<footnote ID="tb3ft1">An adverse reaction is any adverse event which met any of the following criteria: (a) an adverse event that began within 72 hours following the end of product infusion, or (b) an adverse event considered by either the investigator or sponsor to be at least possibly related to product administration, or (c) an adverse event for which causality assessment was missing or indeterminate.</footnote> Frequency as a % of all Infusions (≥ 0.5%)</caption><col width="34%" align="left"/><col width="33%" align="left"/><col width="33%" align="left"/><thead><tr><th align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">Adverse Reactions (AR)</th><th align="center" valign="top" styleCode="Toprule Botrule Rrule">GLASSIA<footnote>Throughout entire 24-week double-blind plus open-label trial period.</footnote> (N<sup>i</sup>=960) No. of adverse reactions<footnoteRef IDREF="tb3ft1"/> (AR) (percentage of all infusions)</th><th align="center" valign="top" styleCode="Toprule Botrule Rrule">Prolastin<footnote>Throughout initial 12-week double-blind period.</footnote> (N<sup>i</sup>=190) No. of adverse reactions<footnoteRef IDREF="tb3ft1"/> (AR) (percentage of all infusions)</th></tr></thead><tfoot><tr><td align="left" colspan="3">N<sup>i</sup>=number of infusions.</td></tr></tfoot><tbody><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule">Upper respiratory tract infection</td><td align="center" valign="top" styleCode="Botrule Rrule">8 (0.8%)</td><td align="center" valign="top" styleCode="Botrule Rrule">0 (0.0%)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule">Headache</td><td align="center" valign="top" styleCode="Botrule Rrule">6 (0.6%)</td><td align="center" valign="top" styleCode="Botrule Rrule">3 (1.6%)</td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule">Nasopharyngitis</td><td align="center" valign="top" styleCode="Botrule Rrule">5 (0.5%)</td><td align="center" valign="top" styleCode="Botrule Rrule">0 (0%)</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.